Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company, has announced the granting of non-statutory stock options to a newly hired non-executive employee. The grant, made on September 3, 2024, covers 2,500 shares of common stock at an exercise price of $25.15 per share, matching the closing price on the Nasdaq Global Select Market that day.
The options were granted under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee. In accordance with Nasdaq Listing Rule 5635(c)(4), this grant serves as a material inducement for the employee's acceptance of employment. The vesting schedule is set for one-third of the shares annually over three years, contingent on continuous service. The options will expire after ten years unless terminated earlier.
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, has announced the granting of non-statutory stock options to two newly hired non-executive employees on August 1, 2024. The options cover 8,850 shares of common stock at an exercise price of $26.29 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
These grants were made under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee. The options will vest over three years, with one-third vesting on each anniversary of the grant date, contingent on continuous service. The options expire after ten years and were granted as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics (NASDAQ: ANIK) reported Q2 2024 financial results. Revenue decreased 5% year-over-year to $41.9 million. OA Pain Management revenue fell 9% to $26.7 million, while Joint Preservation and Restoration revenue rose 7% to $13.5 million. Gross margin was 65%, and adjusted net income stood at $2.5 million or $0.17 per diluted share. Adjusted EBITDA was $6.3 million. The company reported a net loss of $0.1 million or $0.01 per share.
In July 2024, Anika launched the Integrity™ Implant System, an HA-based scaffold for rotator cuff and tendon repairs, achieving over 300 successful cases.
International OA Pain Management revenue grew 17% in H1 2024. Anika announced a $40 million share repurchase program and cost reduction initiatives resulting in $8.8 million adjusted EBITDA year-to-date, up 73% from H1 2023. Fiscal 2024 revenue guidance remains $168-$173 million with a lower-end adjusted EBITDA expectation of $25-$30 million.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced its participation in the upcoming Sidoti Virtual Investor Conference. The event is scheduled for Thursday, August 15, 2024, with Anika's management team set to deliver a virtual presentation followed by a Q&A session starting at 11:30 AM ET.
Investors and interested parties can access the live webcast of the presentation and Q&A through the Investor Relations section of Anika's website at www.anika.com. For those unable to attend the live event, an archived version of the presentation will be made available on the company's website for future reference.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced its plans to release second quarter 2024 financial results after market close on Thursday, August 8, 2024. The company will host an investor conference call on the same day at 5:00 p.m. ET to discuss financial results and business highlights.
Investors can access the conference call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) with the conference ID 1679035. A live audio webcast and accompanying slide presentation will be available in the Investor Relations section of Anika's website at www.anika.com. The call will be archived and accessible on the website shortly after its conclusion.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company, announced on July 16, 2024, that it granted non-statutory stock options to a newly hired non-executive employee on July 1, 2024. The options cover 2,500 shares of common stock at an exercise price of $25.85 per share, matching the closing price on the Nasdaq Global Select Market on the grant date. The grant was made under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee. The options will vest over three years, with one-third vesting on each anniversary of the grant date, contingent on continuous service. The options expire after ten years and were granted as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics has announced the full market release of its Integrity Implant System in the U.S., expanding its hyaluronic acid (HA) regenerative portfolio. The system, designed for rotator cuff and other tendon repairs, includes a HA-based implant and innovative arthroscopic instrumentation. Since its release in November 2023, over 300 surgeries have been performed, showing high market demand. The Integrity system offers superior tensile strength, suture retention, and tear resistance compared to leading collagen implants. It has demonstrated greater regenerative capacity in clinical use, supporting faster and stronger healing in diverse tendon repairs.
The U.S. soft tissue augmentation market, valued at over $190 million and growing at a 7% CAGR, presents significant opportunities in orthopedics. The Integrity Implant System is positioned to become a new standard in tendon repair, with its full market release coinciding with Anika's participation at the 2024 AOSSM Annual Meeting in Denver.
Anika Therapeutics announced inducement grants on June 3, 2024, including non-statutory stock options for 96,525 shares at an exercise price of $29.35 per share and restricted stock units (RSUs) for 38,520 shares. These grants were given to Stephen Griffin, the newly appointed Executive VP, CFO, and Treasurer. The stock options and RSUs will vest over three years, contingent on continuous service. The options expire in ten years unless terminated earlier. The grants were issued under Anika's 2021 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4), and did not require stockholder approval.
Anika Therapeutics announced a cooperation agreement with Caligan Partners, appointing Joseph Capper and William Jellison to its Board of Directors.
Capper, CEO of MIMEDX, and Jellison, former CFO of Stryker, bring nearly 50 years of combined MedTech experience. They will serve on the Capital Allocation Committee. Anika also initiated a $40 million share repurchase program, replacing the previous one from April 2023.
The buyback includes $15 million through a 10b5-1 plan by June 2025 and the rest in the open market by June 2026. Anika aims for $25-$30 million in adjusted EBITDA for 2024, a 75% increase from 2023.
The Board will temporarily expand to ten directors until Jeffrey Thompson's retirement in 2024, post which it will have nine directors. Caligan agrees to support the Board's slate in 2024 and adhere to standstill and voting commitments.
Anika Therapeutics, Inc. announced the appointment of Steve Griffin as the new CFO, effective June 3, 2024. He replaces Michael Levitz, who will stay until December 31, 2024, to ensure a smooth transition. The company aims to accelerate its pivot to profitability with Steve's expertise.